Innovent Biologics Initiates Phase 3 Study of Mazdutide for Treating Obesity and MAFLD in China

Reuters

2025/05/16

Innovent Biologics Initiates Phase 3 Study of Mazdutide for Treating Obesity and MAFLD in China

Innovent Biologics Inc. has announced the commencement of the first participant dosing in their GLORY-3 Phase 3 clinical study in China. This study focuses on evaluating the efficacy and safety of mazdutide, a dual glucagon $(GCG.UK)$ and glucagon-like peptide 1 receptor (GLP-1) receptor agonist, compared to semaglutide in adults with overweight or obesity accompanied by metabolic dysfunction-associated fatty liver disease (MAFLD). The trial aims to enroll approximately 470 participants, assessing primary endpoints such as changes in liver fat content and body weight over 48 weeks. Innovent's Senior Vice President of Clinical Development, Dr. Lei Qian, expressed confidence in mazdutide's potential to provide comprehensive metabolic benefits and a better treatment option for Chinese patients struggling with obesity-related MAFLD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN88842) on May 16, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535802719"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535802719\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535802719?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-16 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535802719","market":"nz","top_or_hot":-1,"title":"Innovent Biologics Initiates Phase 3 Study of Mazdutide for Treating Obesity and MAFLD in China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Initiates Phase 3 Study of Mazdutide for Treating Obesity and MAFLD in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> has announced the commencement of the first participant dosing in their GLORY-3 Phase 3 clinical study in China. This study focuses on evaluating the efficacy and safety of mazdutide, a dual glucagon <a href=\"https://laohu8.com/S/GCG.UK\">$(GCG.UK)$</a> and glucagon-like peptide 1 receptor (GLP-1) receptor agonist, compared to semaglutide in adults with overweight or obesity accompanied by metabolic dysfunction-associated fatty liver disease (MAFLD). The trial aims to enroll approximately 470 participants, assessing primary endpoints such as changes in liver fat content and body weight over 48 weeks. Innovent's Senior Vice President of Clinical Development, Dr. Lei Qian, expressed confidence in mazdutide's potential to provide comprehensive metabolic benefits and a better treatment option for Chinese patients struggling with obesity-related MAFLD.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN88842) on May 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Initiates Phase 3 Study of Mazdutide for Treating Obesity and MAFLD in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Initiates Phase 3 Study of Mazdutide for Treating Obesity and MAFLD in China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-16 08:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Initiates Phase 3 Study of Mazdutide for Treating Obesity and MAFLD in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> has announced the commencement of the first participant dosing in their GLORY-3 Phase 3 clinical study in China. This study focuses on evaluating the efficacy and safety of mazdutide, a dual glucagon <a href=\"https://laohu8.com/S/GCG.UK\">$(GCG.UK)$</a> and glucagon-like peptide 1 receptor (GLP-1) receptor agonist, compared to semaglutide in adults with overweight or obesity accompanied by metabolic dysfunction-associated fatty liver disease (MAFLD). The trial aims to enroll approximately 470 participants, assessing primary endpoints such as changes in liver fat content and body weight over 48 weeks. Innovent's Senior Vice President of Clinical Development, Dr. Lei Qian, expressed confidence in mazdutide's potential to provide comprehensive metabolic benefits and a better treatment option for Chinese patients struggling with obesity-related MAFLD.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN88842) on May 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心資產","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDL3yw2wp:1","article_id":"2535802719","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535802719","pubTimestamp":1747353620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics Inc. has announced the commencement of the first participant dosing in their GLORY-3 Phase 3 clinical study in China. This study focuses on evaluating the efficacy and safety of mazdutide, a dual glucagon  and glucagon-like peptide 1 receptor  receptor agonist, compared to semaglutide in adults with overweight or obesity accompanied by metabolic dysfunction-associated fatty liver disease . The trial aims to enroll approximately 470 participants, assessing primary endpoints such as changes in liver fat content and body weight over 48 weeks. Innovent's Senior Vice President of Clinical Development, Dr. Lei Qian, expressed confidence in mazdutide's potential to provide comprehensive metabolic benefits and a better treatment option for Chinese patients struggling with obesity-related MAFLD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1147":"投资银行业与经纪业","01801":"信达生物","BK1161":"生物科技","01911":"华兴资本控股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1583":"高瓴概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC"},"translate_title":"信达生物在中国启动Mazdutide治疗肥胖和MAFLD的3期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9,"01911":0.9},"content_text":"Innovent Biologics Initiates Phase 3 Study of Mazdutide for Treating Obesity and MAFLD in China\n    \n\nInnovent Biologics Inc. has announced the commencement of the first participant dosing in their GLORY-3 Phase 3 clinical study in China. This study focuses on evaluating the efficacy and safety of mazdutide, a dual glucagon $(GCG.UK)$ and glucagon-like peptide 1 receptor (GLP-1) receptor agonist, compared to semaglutide in adults with overweight or obesity accompanied by metabolic dysfunction-associated fatty liver disease (MAFLD). The trial aims to enroll approximately 470 participants, assessing primary endpoints such as changes in liver fat content and body weight over 48 weeks. Innovent's Senior Vice President of Clinical Development, Dr. Lei Qian, expressed confidence in mazdutide's potential to provide comprehensive metabolic benefits and a better treatment option for Chinese patients struggling with obesity-related MAFLD.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN88842) on May 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}